What is it about?
Oligomeric amyloid β (OAβ), an upstream driver of Alzheimer’s disease (AD) neuropathology, correlates well with cognitive performance as measured by the language neutral Visual Cognitive Assessment Test (VCAT), as well as grey matter volume (GMV) in a Southeast Asian cohort of mild cognitive impairment (MCI) patients. Higher plasma OAβ levels significantly correlated with lower cognitive scores (VCAT, Mini-Mental State Examination) and greater brain atrophy as measured by GMV.
Featured Image
Why is it important?
Such findings are noteworthy as they reveal the clinical utility of plasma OAβ as a promising blood-based biomarker that can be routinely used in the clinic to support clinicians in making a diagnosis of AD.
Perspectives
OAβ is an accessible species of amyloid β, which is detectable in peripheral circulation and therefore holds promise in its abilities to provide an accurate biological representation of Alzheimer’s Disease. As a result, it has strong utility in research (clinical and medical), specifically in diagnostics, prognostication, disease stratification and therapeutic intervention, and should be evaluated thoroughly in its abilities to be a potent biomarker. Furthermore, the VCAT being a language neutral cognitive assessment tool, has a wider outreach towards global populations, and therefore serves as a robust support for neurocognitive evaluation, with the capacity to depict early disease associated changes, which correlates with Aβ positivity.
Nagaendran Kandiah
Nanyang Technological University
Read the Original
This page is a summary of: Correlation Between Plasma Oligomeric Amyloid-β and Performance on the Language Neutral Visual Cognitive Assessment Test in a Southeast Asian Population, Journal of Alzheimer s Disease, August 2022, IOS Press,
DOI: 10.3233/jad-220484.
You can read the full text:
Contributors
The following have contributed to this page
